OTC · QSAM
QSAM Biosciences, Inc.
Healthcare · Biotechnology
$8.30
Down-$16,591.70 (-99.95%)
Updated Sep 16, 2026, 1:02 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 18.44K
- P/E ratio
- -6.67
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 133.56K
- Avg. volume
- 6.1K
Price performance
QSAM price history
1M range · 0 trading sessions · Daily adjusted prices
QSAM does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest QSAM news
The latest Smart Investors Daily articles mentioning QSAM.
Stock researchCompany · Overview
QSAM research
Overview
Company profile and research snapshot.
Company profile
QSAM Biosciences, Inc. engages in developing various nuclear medicines for the treatment of cancer and related diseases. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage bone targeting radiopharmaceutical. It has a license agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020. QSAM Biosciences, Inc. was incorporated in 2004 and is headquartered in Austin, Texas.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
